PT1137436E - Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 - Google Patents
Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 Download PDFInfo
- Publication number
- PT1137436E PT1137436E PT99965991T PT99965991T PT1137436E PT 1137436 E PT1137436 E PT 1137436E PT 99965991 T PT99965991 T PT 99965991T PT 99965991 T PT99965991 T PT 99965991T PT 1137436 E PT1137436 E PT 1137436E
- Authority
- PT
- Portugal
- Prior art keywords
- ctla
- self antigens
- stimulation
- blocking agents
- against self
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11076198P | 1998-12-03 | 1998-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1137436E true PT1137436E (pt) | 2008-09-15 |
Family
ID=22334796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99965991T PT1137436E (pt) | 1998-12-03 | 1999-12-03 | Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1137436B1 (pt) |
JP (1) | JP5341287B2 (pt) |
AT (1) | ATE397457T1 (pt) |
AU (1) | AU774962B2 (pt) |
CA (1) | CA2352783C (pt) |
CY (1) | CY1108318T1 (pt) |
DE (1) | DE69938871D1 (pt) |
DK (1) | DK1137436T3 (pt) |
ES (1) | ES2308857T3 (pt) |
PT (1) | PT1137436E (pt) |
WO (1) | WO2000032231A1 (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
CN1371416B (zh) * | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
ES2402546T3 (es) | 2000-06-28 | 2013-05-06 | Genetics Institute, Llc | Moléculas PD-L2: nuevos ligandos de PD-1 y usos de lso mismos |
PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
CN1240436C (zh) * | 2002-08-28 | 2006-02-08 | 上海益众生物技术有限公司 | 成骨生长肽与粒细胞集落刺激因子在造血方面的协同作用 |
JP2006522101A (ja) * | 2003-03-12 | 2006-09-28 | デューク・ユニバーシティー | オリゴヌクレオチド類似体 |
US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
US7494779B2 (en) | 2004-06-14 | 2009-02-24 | Li-Te Chin | Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
WO2006124667A2 (en) | 2005-05-12 | 2006-11-23 | Zymogenetics, Inc. | Compositions and methods for modulating immune responses |
KR101600225B1 (ko) | 2005-06-08 | 2016-03-04 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(pd-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
CA2630157C (en) | 2005-12-07 | 2018-01-09 | Medarex, Inc. | Ctla-4 antibody dosage escalation regimens |
CA2744449C (en) | 2008-11-28 | 2019-01-29 | Emory University | Methods for the treatment of infections and tumors |
CN102740887B (zh) | 2009-09-30 | 2015-04-15 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
US8435516B2 (en) | 2009-10-12 | 2013-05-07 | Pfizer Inc. | Cancer treatment |
DK2844282T3 (da) * | 2012-05-04 | 2019-07-15 | Pfizer | Prostata-associerede antigener og vaccine-baserede immunterapiregimener |
WO2013169971A1 (en) | 2012-05-10 | 2013-11-14 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
EA201691073A1 (ru) | 2013-12-05 | 2016-12-30 | РФЕМБ ХОЛДИНГС, ЭлЭлСи | Иммунотерапия рака с помощью радиочастотного электрического пробоя мембраны (rf-emb) |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
NZ734144A (en) | 2014-12-31 | 2023-06-30 | Checkmate Pharmaceuticals Inc | Combination tumor immunotherapy |
PT3273992T (pt) | 2015-03-23 | 2020-08-21 | Jounce Therapeutics Inc | Anticorpos para icos |
EP3303394B1 (en) | 2015-05-29 | 2020-04-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
US10968277B2 (en) | 2015-10-22 | 2021-04-06 | Jounce Therapeutics, Inc. | Gene signatures for determining ICOS expression |
US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
CA3011460A1 (en) * | 2016-01-15 | 2017-07-20 | Rfemb Holdings, Llc | Immunologic treatment of cancer |
AU2017373944B2 (en) | 2016-12-07 | 2022-02-03 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
CN110300599A (zh) | 2016-12-07 | 2019-10-01 | 艾吉纳斯公司 | 抗体和其使用方法 |
JP2020509037A (ja) | 2017-02-28 | 2020-03-26 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ワクチンに対する免疫応答を増強するための、adccが増強された抗ctla−4抗体の使用 |
EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
CN112105645A (zh) | 2018-04-18 | 2020-12-18 | Xencor股份有限公司 | Il-15/il-15ra异二聚体fc融合蛋白及其用途 |
US20210236694A1 (en) * | 2018-05-03 | 2021-08-05 | The Johns Hopkins University | Induction of anti-tumoral immune microenvironments |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
CR20210239A (es) | 2018-10-12 | 2021-12-15 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas |
WO2021067863A2 (en) | 2019-10-03 | 2021-04-08 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
JP7405361B2 (ja) | 2019-10-21 | 2023-12-26 | 東亞合成株式会社 | 抗腫瘍ペプチドおよびその利用 |
JP7498889B2 (ja) | 2020-01-30 | 2024-06-13 | 東亞合成株式会社 | Ctla4とb7タンパク質との結合を抑制するペプチドおよびその利用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL92382A (en) * | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
JP2001523958A (ja) * | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
CN1371416B (zh) * | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
-
1999
- 1999-12-03 EP EP99965991A patent/EP1137436B1/en not_active Expired - Lifetime
- 1999-12-03 WO PCT/US1999/028739 patent/WO2000032231A1/en active IP Right Grant
- 1999-12-03 PT PT99965991T patent/PT1137436E/pt unknown
- 1999-12-03 ES ES99965991T patent/ES2308857T3/es not_active Expired - Lifetime
- 1999-12-03 AT AT99965991T patent/ATE397457T1/de active
- 1999-12-03 CA CA2352783A patent/CA2352783C/en not_active Expired - Lifetime
- 1999-12-03 JP JP2000584920A patent/JP5341287B2/ja not_active Expired - Lifetime
- 1999-12-03 AU AU21649/00A patent/AU774962B2/en not_active Expired
- 1999-12-03 DK DK99965991T patent/DK1137436T3/da active
- 1999-12-03 DE DE69938871T patent/DE69938871D1/de not_active Expired - Lifetime
-
2008
- 2008-09-04 CY CY20081100953T patent/CY1108318T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2308857T3 (es) | 2008-12-01 |
CA2352783C (en) | 2012-04-10 |
JP5341287B2 (ja) | 2013-11-13 |
WO2000032231A1 (en) | 2000-06-08 |
ATE397457T1 (de) | 2008-06-15 |
JP2002531416A (ja) | 2002-09-24 |
EP1137436B1 (en) | 2008-06-04 |
AU774962B2 (en) | 2004-07-15 |
CA2352783A1 (en) | 2000-06-08 |
AU2164900A (en) | 2000-06-19 |
DK1137436T3 (da) | 2008-10-13 |
EP1137436A1 (en) | 2001-10-04 |
CY1108318T1 (el) | 2014-02-12 |
DE69938871D1 (de) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1137436E (pt) | Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 | |
TW376320B (en) | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma | |
ES2163034T3 (es) | Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana. | |
CA2149329A1 (en) | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma | |
ZA944347B (en) | The use of cetrorelix and other nona- and decapeptides in the preparation of a medicament for combating aids and for growth stimulation | |
EP1025856A3 (en) | Methods for modulating T Cell unresponsiveness | |
CY1105818T1 (el) | Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου | |
AU6649996A (en) | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease | |
WO1997002046A3 (de) | Saccharid-konjugate | |
ATE420175T1 (de) | C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen | |
EP0959896A4 (en) | COMPOSITIONS BASED ON THE HUMAN THYROTROPIN RECEPTOR AND THEIR USE | |
WO2002066044A3 (en) | Method for dendritic cells based immunotherapy of tumors using combination therapy | |
FR2772622B1 (fr) | Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur et/ou cardioverteur, de type multisite configurable | |
IL123642A (en) | Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration | |
AU8239298A (en) | Nucleotide-comprising composition | |
DK0855916T3 (da) | Farmaceutisk præparat indeholdende en Activin-stimulator | |
CA2194485A1 (en) | Endothelial lining effects and treatment of vasospastic disorders | |
IL131478A0 (en) | Methods for treatment of scar tissue | |
GB0102145D0 (en) | Substances | |
GB2204497A (en) | Electrode assembly for transdermal drug delivery | |
PL330535A1 (en) | Novel systems for transcutaneous administration of trimegestone, method of preparing them for use and their application as therapeutic agents | |
HK1046847A1 (en) | Pharmaceutical combination with analgesic action containing paracetamol and buspirone. | |
FR2786699B1 (fr) | Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles | |
MD1119G2 (ro) | Metodă de tratament al afecţiunilor inflamatorii ale organelor genitale feminine | |
DE69724228D1 (de) | Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten |